- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04317430
Niclosamide Role in Diabetic Nephropathy
Possible Role of Niclosamide in Patients With Diabetic Kidney Disease: Randomized Controlled Study
This study is randomized, controlled, parallel, prospective clinical study will be conducted on 60 patients diagnosed with type 2 diabetes mellitus at least five years ago. Patients will be recruited from Tanta University Hospital, Tanta, Egypt.
Accepted patients will be randomized into 2 groups as the following:
Control group: 30 patients will receive maximum tolerated dose of ACEI plus placebo pills for six months Treatment group: 30 patients will receive maximum tolerated dose of ACEI plus niclosamide tablets 1 gram once daily for six months The primary end point will be the change in Urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) after six months of treatment
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Tanta, Egypt
- Faculty of Pharmacy, Tanta University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with Type 2 diabetes mellitus at least 5 years ago
- Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary albumin creatinine ratio (UACR) >30mg/g) despite treatment with maximum tolerated dose of ACE inhibitors for at least 8 weeks prior to the screening
- Hemoglobin A1c > 6.5 % with regular use of insulin and/or oral glucose lowering agents
Exclusion Criteria:
- Type 1 diabetes mellitus
- Severe renal impairment (eGFR< 30 mL/min/1.73 m2 at screening)
- Pregnant or lactating women
- Chronic heart failure
- Inflammatory or autoimmune disease
- History of kidney disease other than diabetic nephropathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Treatment group
Niclosamide tablets 1 gram once daily
|
Niclosamide tablets 1 gram once daily
|
PLACEBO_COMPARATOR: Control group
Lactose tablets
|
lactose tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in urinary albumin creatinine ratio (UACR)
Time Frame: 6 months
|
6 months
|
Estimated glomerular filtration rate (eGFR)
Time Frame: After 6 months
|
After 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of Urinary matrix metalloproteinase-7 (MMP-7) level
Time Frame: 6 months
|
6 months
|
Change of Urinary podocalyxin level
Time Frame: 6 months
|
6 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of Urinary 8-hydroxy-2' -deoxyguanosine (8-OHdG) level
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIC2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathies
-
NephroGenex, Inc.Medpace, Inc.; Collaborative Study Group (CSG)TerminatedDiabetic Nephropathy | Diabetic Kidney DiseaseUnited States, Australia, Bulgaria, France, Germany, Hong Kong, Hungary, Israel, Mauritius, Poland, Puerto Rico, Spain
-
University of MilanActive, not recruitingDiabetic Nephropathy Type 2Italy
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
Clinical Trials on Niclosamide
-
University of BaghdadRecruitingCovid-19 | SARS PneumoniaIraq
-
TFF Pharmaceuticals, Inc.Completed
-
Imuneks Farma ilac San. Tic. A.S.Unknown
-
Charité Research Organisation GmbHBayerTerminated
-
Yonsei UniversityRecruiting
-
First Wave Bio, Inc.TerminatedUlcerative Colitis | Ulcerative Proctitis | Ulcerative ProctosigmoiditisItaly
-
Charite University, Berlin, GermanyCenter for Molecular MedicineUnknown
-
National Institute of Allergy and Infectious Diseases...Terminated